How can grafted breast cancer models be optimized?
Breast cancer is the most frequent spontaneous malignancy diagnosed in women and is characterized by a broad histological diversity. Progression of the disease has a metastasizing trend and can be resistant to hormonal and chemotherapy. Animal models have provided some understanding of these feature...
Gespeichert in:
| Veröffentlicht in: | Cancer biology & therapy 2011-11, Vol.12 (10), p.855-864 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 864 |
|---|---|
| container_issue | 10 |
| container_start_page | 855 |
| container_title | Cancer biology & therapy |
| container_volume | 12 |
| creator | Mollard, Séverine Mousseau, Yoanne Baaj, Yasser Richard, Laurence Cook-Moreau, Jeanne Monteil, Jacques Funalot, Benoît Sturtz, Franck G. |
| description | Breast cancer is the most frequent spontaneous malignancy diagnosed in women and is characterized by a broad histological diversity. Progression of the disease has a metastasizing trend and can be resistant to hormonal and chemotherapy. Animal models have provided some understanding of these features and have allowed new treatments to be proposed. However, these models need to be revised because they have some limitations in predicting the clinical efficacy of new therapies. In this review, we discuss the biological criteria to be taken into account for a realistic animal model of breast cancer graft (tumor implantation site, animal immune status, histological diversity, modern imaging). We emphasize the need for more stringent monitoring criteria, and suggest adopting the human RECIST (Response Evaluation Criteria in Solid Tumors) criteria to evaluate treatments in animal models. |
| doi_str_mv | 10.4161/cbt.12.10.18139 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3280900</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>912796436</sourcerecordid><originalsourceid>FETCH-LOGICAL-c527t-f6abaf98fea77921d6ff50ec1bf219ab25725fa42505fe507f6732dd58f8e80d3</originalsourceid><addsrcrecordid>eNqNkc1vFSEUxYnR2A9duzOzczWvXGYYBhea-lJtkyYmpq4JA5eKmRmewLNp__oyvvqsCxNXcOF3zz0cCHkFdNVCBydmyCtgq1JCD418Qg6Bc173XHRPl33T1y1txQE5Suk7pUywTj4nB4xRLhiIQ8LOw01l9FxdR-0y2mqIqFNejgzGagoWx1QNWIVN9pO_Q_v-BXnm9Jjw5cN6TL5-PLtan9eXnz9drE8va8OZyLXr9KCd7B1qISQD2znHKRoYHAOpB1YccKdbxil3yKlwnWiYtbx3PfbUNsfk3U53sx0mtAbnHPWoNtFPOt6qoL36-2b239R1-Kka1lNJaRF48yAQw48tpqwmnwyOo54xbJOSwITs2qYr5MmONDGkFNHtpwBVS9CqBK2ALeWvoEvH68fm9vzvZAsAO6BMs5gGH5LxWEL9g1KA9YerVrbiC6iNdf_Rs9jQMXsz4t7I212Pn12Ik74JcbQq69sxRBfLL_qkmn-94h7NSrDr</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>912796436</pqid></control><display><type>article</type><title>How can grafted breast cancer models be optimized?</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Mollard, Séverine ; Mousseau, Yoanne ; Baaj, Yasser ; Richard, Laurence ; Cook-Moreau, Jeanne ; Monteil, Jacques ; Funalot, Benoît ; Sturtz, Franck G.</creator><creatorcontrib>Mollard, Séverine ; Mousseau, Yoanne ; Baaj, Yasser ; Richard, Laurence ; Cook-Moreau, Jeanne ; Monteil, Jacques ; Funalot, Benoît ; Sturtz, Franck G.</creatorcontrib><description>Breast cancer is the most frequent spontaneous malignancy diagnosed in women and is characterized by a broad histological diversity. Progression of the disease has a metastasizing trend and can be resistant to hormonal and chemotherapy. Animal models have provided some understanding of these features and have allowed new treatments to be proposed. However, these models need to be revised because they have some limitations in predicting the clinical efficacy of new therapies. In this review, we discuss the biological criteria to be taken into account for a realistic animal model of breast cancer graft (tumor implantation site, animal immune status, histological diversity, modern imaging). We emphasize the need for more stringent monitoring criteria, and suggest adopting the human RECIST (Response Evaluation Criteria in Solid Tumors) criteria to evaluate treatments in animal models.</description><identifier>ISSN: 1538-4047</identifier><identifier>EISSN: 1555-8576</identifier><identifier>DOI: 10.4161/cbt.12.10.18139</identifier><identifier>PMID: 22057217</identifier><language>eng</language><publisher>United States: Taylor & Francis</publisher><subject>animal model ; Animals ; Antineoplastic Agents - therapeutic use ; Binding ; Biology ; Bioscience ; breast cancer ; Breast Neoplasms - diagnosis ; Breast Neoplasms - drug therapy ; Calcium ; Cancer ; Cell ; Cycle ; Disease Models, Animal ; Female ; Humans ; Landes ; monitoring ; Neoplasm Transplantation ; Organogenesis ; orthotopic graft ; Proteins ; Review ; syngeneic ; Treatment Outcome ; Xenograft Model Antitumor Assays</subject><ispartof>Cancer biology & therapy, 2011-11, Vol.12 (10), p.855-864</ispartof><rights>Copyright © 2011 Landes Bioscience 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c527t-f6abaf98fea77921d6ff50ec1bf219ab25725fa42505fe507f6732dd58f8e80d3</citedby><cites>FETCH-LOGICAL-c527t-f6abaf98fea77921d6ff50ec1bf219ab25725fa42505fe507f6732dd58f8e80d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3280900/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3280900/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22057217$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mollard, Séverine</creatorcontrib><creatorcontrib>Mousseau, Yoanne</creatorcontrib><creatorcontrib>Baaj, Yasser</creatorcontrib><creatorcontrib>Richard, Laurence</creatorcontrib><creatorcontrib>Cook-Moreau, Jeanne</creatorcontrib><creatorcontrib>Monteil, Jacques</creatorcontrib><creatorcontrib>Funalot, Benoît</creatorcontrib><creatorcontrib>Sturtz, Franck G.</creatorcontrib><title>How can grafted breast cancer models be optimized?</title><title>Cancer biology & therapy</title><addtitle>Cancer Biol Ther</addtitle><description>Breast cancer is the most frequent spontaneous malignancy diagnosed in women and is characterized by a broad histological diversity. Progression of the disease has a metastasizing trend and can be resistant to hormonal and chemotherapy. Animal models have provided some understanding of these features and have allowed new treatments to be proposed. However, these models need to be revised because they have some limitations in predicting the clinical efficacy of new therapies. In this review, we discuss the biological criteria to be taken into account for a realistic animal model of breast cancer graft (tumor implantation site, animal immune status, histological diversity, modern imaging). We emphasize the need for more stringent monitoring criteria, and suggest adopting the human RECIST (Response Evaluation Criteria in Solid Tumors) criteria to evaluate treatments in animal models.</description><subject>animal model</subject><subject>Animals</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Binding</subject><subject>Biology</subject><subject>Bioscience</subject><subject>breast cancer</subject><subject>Breast Neoplasms - diagnosis</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Calcium</subject><subject>Cancer</subject><subject>Cell</subject><subject>Cycle</subject><subject>Disease Models, Animal</subject><subject>Female</subject><subject>Humans</subject><subject>Landes</subject><subject>monitoring</subject><subject>Neoplasm Transplantation</subject><subject>Organogenesis</subject><subject>orthotopic graft</subject><subject>Proteins</subject><subject>Review</subject><subject>syngeneic</subject><subject>Treatment Outcome</subject><subject>Xenograft Model Antitumor Assays</subject><issn>1538-4047</issn><issn>1555-8576</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><sourceid>EIF</sourceid><recordid>eNqNkc1vFSEUxYnR2A9duzOzczWvXGYYBhea-lJtkyYmpq4JA5eKmRmewLNp__oyvvqsCxNXcOF3zz0cCHkFdNVCBydmyCtgq1JCD418Qg6Bc173XHRPl33T1y1txQE5Suk7pUywTj4nB4xRLhiIQ8LOw01l9FxdR-0y2mqIqFNejgzGagoWx1QNWIVN9pO_Q_v-BXnm9Jjw5cN6TL5-PLtan9eXnz9drE8va8OZyLXr9KCd7B1qISQD2znHKRoYHAOpB1YccKdbxil3yKlwnWiYtbx3PfbUNsfk3U53sx0mtAbnHPWoNtFPOt6qoL36-2b239R1-Kka1lNJaRF48yAQw48tpqwmnwyOo54xbJOSwITs2qYr5MmONDGkFNHtpwBVS9CqBK2ALeWvoEvH68fm9vzvZAsAO6BMs5gGH5LxWEL9g1KA9YerVrbiC6iNdf_Rs9jQMXsz4t7I212Pn12Ik74JcbQq69sxRBfLL_qkmn-94h7NSrDr</recordid><startdate>20111115</startdate><enddate>20111115</enddate><creator>Mollard, Séverine</creator><creator>Mousseau, Yoanne</creator><creator>Baaj, Yasser</creator><creator>Richard, Laurence</creator><creator>Cook-Moreau, Jeanne</creator><creator>Monteil, Jacques</creator><creator>Funalot, Benoît</creator><creator>Sturtz, Franck G.</creator><general>Taylor & Francis</general><general>Landes Bioscience</general><scope>0YH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20111115</creationdate><title>How can grafted breast cancer models be optimized?</title><author>Mollard, Séverine ; Mousseau, Yoanne ; Baaj, Yasser ; Richard, Laurence ; Cook-Moreau, Jeanne ; Monteil, Jacques ; Funalot, Benoît ; Sturtz, Franck G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c527t-f6abaf98fea77921d6ff50ec1bf219ab25725fa42505fe507f6732dd58f8e80d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>animal model</topic><topic>Animals</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Binding</topic><topic>Biology</topic><topic>Bioscience</topic><topic>breast cancer</topic><topic>Breast Neoplasms - diagnosis</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Calcium</topic><topic>Cancer</topic><topic>Cell</topic><topic>Cycle</topic><topic>Disease Models, Animal</topic><topic>Female</topic><topic>Humans</topic><topic>Landes</topic><topic>monitoring</topic><topic>Neoplasm Transplantation</topic><topic>Organogenesis</topic><topic>orthotopic graft</topic><topic>Proteins</topic><topic>Review</topic><topic>syngeneic</topic><topic>Treatment Outcome</topic><topic>Xenograft Model Antitumor Assays</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mollard, Séverine</creatorcontrib><creatorcontrib>Mousseau, Yoanne</creatorcontrib><creatorcontrib>Baaj, Yasser</creatorcontrib><creatorcontrib>Richard, Laurence</creatorcontrib><creatorcontrib>Cook-Moreau, Jeanne</creatorcontrib><creatorcontrib>Monteil, Jacques</creatorcontrib><creatorcontrib>Funalot, Benoît</creatorcontrib><creatorcontrib>Sturtz, Franck G.</creatorcontrib><collection>Taylor & Francis Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer biology & therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mollard, Séverine</au><au>Mousseau, Yoanne</au><au>Baaj, Yasser</au><au>Richard, Laurence</au><au>Cook-Moreau, Jeanne</au><au>Monteil, Jacques</au><au>Funalot, Benoît</au><au>Sturtz, Franck G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>How can grafted breast cancer models be optimized?</atitle><jtitle>Cancer biology & therapy</jtitle><addtitle>Cancer Biol Ther</addtitle><date>2011-11-15</date><risdate>2011</risdate><volume>12</volume><issue>10</issue><spage>855</spage><epage>864</epage><pages>855-864</pages><issn>1538-4047</issn><eissn>1555-8576</eissn><abstract>Breast cancer is the most frequent spontaneous malignancy diagnosed in women and is characterized by a broad histological diversity. Progression of the disease has a metastasizing trend and can be resistant to hormonal and chemotherapy. Animal models have provided some understanding of these features and have allowed new treatments to be proposed. However, these models need to be revised because they have some limitations in predicting the clinical efficacy of new therapies. In this review, we discuss the biological criteria to be taken into account for a realistic animal model of breast cancer graft (tumor implantation site, animal immune status, histological diversity, modern imaging). We emphasize the need for more stringent monitoring criteria, and suggest adopting the human RECIST (Response Evaluation Criteria in Solid Tumors) criteria to evaluate treatments in animal models.</abstract><cop>United States</cop><pub>Taylor & Francis</pub><pmid>22057217</pmid><doi>10.4161/cbt.12.10.18139</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1538-4047 |
| ispartof | Cancer biology & therapy, 2011-11, Vol.12 (10), p.855-864 |
| issn | 1538-4047 1555-8576 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3280900 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | animal model Animals Antineoplastic Agents - therapeutic use Binding Biology Bioscience breast cancer Breast Neoplasms - diagnosis Breast Neoplasms - drug therapy Calcium Cancer Cell Cycle Disease Models, Animal Female Humans Landes monitoring Neoplasm Transplantation Organogenesis orthotopic graft Proteins Review syngeneic Treatment Outcome Xenograft Model Antitumor Assays |
| title | How can grafted breast cancer models be optimized? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T18%3A04%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=How%20can%20grafted%20breast%20cancer%20models%20be%20optimized?&rft.jtitle=Cancer%20biology%20&%20therapy&rft.au=Mollard,%20S%C3%A9verine&rft.date=2011-11-15&rft.volume=12&rft.issue=10&rft.spage=855&rft.epage=864&rft.pages=855-864&rft.issn=1538-4047&rft.eissn=1555-8576&rft_id=info:doi/10.4161/cbt.12.10.18139&rft_dat=%3Cproquest_pubme%3E912796436%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=912796436&rft_id=info:pmid/22057217&rfr_iscdi=true |